Moderna (MRNA) Jumps 176.97% After Cancer Vaccine Trial Hits Phase 3 Endpoints

Moderna and Merck set off a historic repricing in the biotech sector after announcing that the Phase 3 INTerpath-001 trial, testing the investigational mRNA cancer vaccine intismeran autogene alongside Merck’s Keytruda, met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival in patients with fully resected stage IIB-IV melanoma. Moderna shares closed the session up 176.97%, near $174, the largest single-day gain in the company’s history, and its market capitalization swelled from roughly $25 billion to about $69 billion overnight. Partner Merck climbed more than 12.60% to $152.20, also reaching an all-time high. The readout lifted a broad basket of biopharma names, with BioNTech, AbbVie, Amgen, Eli Lilly and Johnson & Johnson all touching record levels. Moderna’s official press release framed the result as the first successful Phase 3 trial for an mRNA cancer therapy and the first for a personalized neoantigen approach, a validation point for the platform after COVID-19 vaccine demand faded. Leerink Partners analysts called the outcome “historic,” while the companies said they would present complete results at a medical congress and discuss regulatory filing; Moderna chief executive Stéphane Bancel suggested approval could come as early as 2027. The trial enrolled 1,137 patients in a 2:1 randomized, double-blind design, and the combination was given as an adjuvant regimen lasting roughly 56 weeks — nine doses of intismeran every three weeks plus nine cycles of Keytruda every six weeks. Even with the strong readout, the full effect-size data, including hazard ratios and confidence intervals, has not yet been disclosed. Analysts noted that the clinical breakthrough provides fundamental support for a sector that had lagged as capital concentrated in technology and semiconductor stocks during the post-pandemic period, and the gains suggest rotation into healthcare may be underway.

Beyond the headline return, the therapy is a personalized treatment rather than a preventive vaccine. The drug is built by sequencing a patient’s tumor, identifying mutations that are unique to the cancer, and using an algorithm to select up to 34 neoantigens — protein markers absent from healthy cells. Those sequences are encoded in mRNA and wrapped in lipid nanoparticles to train T cells to recognize the tumor. The entire manufacturing process, from biopsy to first injection, takes about six weeks, according to the company’s description. Melanoma was the first target partly because it has one of the highest tumor mutation burdens, with a median of roughly 276 nonsynonymous mutations, giving the algorithm more material to work with than lower-mutation cancers such as pancreatic cancer. The INTerpath program is meanwhile testing the platform in nine Phase 2 and Phase 3 trials across non-small cell lung, bladder, kidney, pancreatic and gastric cancers, though the current trial excluded ocular and mucosal melanoma and unresectable metastatic disease. Importantly, this is an adjuvant therapy — designed to prevent recurrence after surgery, not to treat patients with already widespread disease. The interim analysis that sparked the rally disclosed only that the trial met its endpoints; it did not include hazard ratios, p-values, event counts or Kaplan-Meier curves, and overall survival data remain immature. The only concrete efficacy signal available comes from the earlier Phase 2 KEYNOTE-942 study of 157 patients, which showed a 49% reduction in the risk of recurrence or death (HR 0.51, 95% CI 0.294-0.887) and a 59% reduction in the risk of distant metastasis or death (HR 0.411, 95% CI 0.200-0.843), with four-year recurrence-free survival of 72.4% versus 49.1% for Keytruda alone. Investors are therefore pricing a platform narrative off an interim readout whose final data is not expected to be complete until 2030.

Taken together, the market move and the clinical explainer frame the same event: the official INTerpath-001 readout released by Moderna and Merck is a primary-source catalyst that compressed months of clinical uncertainty into one 176.97% repricing. What made the move resemble an altcoin-style breakout was narrative and positioning, not the disclosed evidence, which still lacks hazard ratios and survival curves. Citi analysts described Moderna’s pipeline as a “show-me story,” underlining that the first vertical jump can fade if the full data disappoint. For crypto readers, the episode is a reminder that an all-time-high move built on a single document needs confirmation — much like an airdrop-fueled rally depends on follow-through, and momentum can be amplified by AI trading bot flows before fundamentals are confirmed.